November 9, 2020 — Advances in high throughput measurement technologies (omics data) have made it possible, and increasingly affordable, to generate high complexity, high volume data for oncology research. QuartzBio’s Renee Deehan poster, “Reverse Causal Inferencing on Lung Adenocarcinoma Patients Reveals a Stem Cell–Like Molecular Subtype Associated with Pack-Year History,” is an insightful look into an exciting area of opportunity.
Reverse causal inferencing on molecular data from lung adenocarcinoma patients reveals a stem cell–like molecular subtype associated with pack-year history
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO logo® are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved. The names and logos of other companies and products appearing on the website may be trademarks or registered trademarks of such other companies.